Life Sciences Archive » April, 2015

Life Sciences - April, 2015

369 articles

• NJ Doc Gets Year In Prison In $100M Lab Bribery Scheme
• Discovery Tightened In FTC's AbbVie Pay-For-Delay Suit
• Critics Call Newly Released Medicare Part D Data Confusing
• GOP Sens. Knock 'Opaque' FDA Stand On Biosimilars
• Cherokees Seek Share Of $2.4B Actos Deal On Behalf Of Tribes
• Glaucoma Drug Co. Hit With Class Action After Trial Tanks
• FDA To Investigate Hospital Hand Sanitizer Safety
• Mayer Brown Reps Dow Chemical In Latest Unit Sale For $860M
• Paul Weiss Fights Med. Co. Liquidator's Bid For Docs
• Amgen Tells Fed. Circ. Sandoz Would 'Gut' Biosimilar Law
• Agriculture Biotech Co. Arcadia Sets Sights On $100M IPO
• Allergan Asks Judge To Nix Off-Label Botox Suit
• Judge Won't Block FDA's Generic Abilify Approvals
• 5 Tips For Preparing Expert Witnesses In Products Cases
• Accredo Pays $45M To Escape Novartis Exjade Kickback Suit
• GSK Wants Info On Expert For Reed Smith Atty's Wife
• FTC Is No Longer DOJ's Little Brother In Antitrust Remedies
• ViroPharma Prescribes $8M To Cure Investor Suit
• Blueprint Medicines Upsizes IPO Amid Cancer Biotech Craze
• Biotech Exec Lauds Bill To Ease Small-Company Disclosures
• Dendreon Shareholders Lose Bid For Equity Committee
• 4 Tips To Help Your Client Ward Off Unwanted Advances
• FDA Says Abilify Promo Is Misleading
• Eli Lilly Keeps Employees' Salary Info From Cymbalta Suit
• Embattled Ariad CEO To Step Down In Sarissa Deal
• 3rd Circ. Tosses Fen-Phen Injury Suit Against Wyeth
• Chinese Pharma Co. Derivative Suit Premature, Judge Rules
• House Leaders Unveil Dialed-Back FDA Overhaul Bill
• Aveo Board Dumps Cancer Drug Derivative Suit
• Critics Rip Big Pharma Alternative To FDA Warning Label Plan
• TIG Gets Coverage For Stryker Knee Deals Capped At $6.2M
• GW Seeks To Grow Cannabinoid Products With $179M Offering
• Mylan Ups Perrigo Offer To $35.6B, But Rejected Again
• The Satisfaction Of A Refund, Or Your Class Action Back
• FDA Clears Abilify Generics Despite Otsuka Objections
• FDA Finalizes 3 Biosimilars Guidances
• Consumers Seek $5M In Suit Over 'Magical' Anti-Aging Serum
• Bipartisan Bill To Lift Veil On Fed. Settlements Reintroduced
• Washington Tribal Marijuana Pact Bill Heads To Governor
• Takeda Will Pay Up To $2.4B To Resolve Actos Suits
• Device Maker Accused Of Firing Accountant Over FCA Claims
• HTG Prepares To Test Investor Appetite For Diagnostics
• Novartis Unit Beats Cataract Lens Injury Suit
• Allergan Can Be Liable Under FCA In Kickback Suit, Gov't Says
• SAC Capital Ducks Investors' Racketeering Claims
• 5th Circ. Urged To Rehear Off-Label Reglan Claims
• Judge Says Tribal Court Should Hear Actos Suit
• FDA Launches Fresh Crackdown On Supplement Cos.
• Howmedica Pays $3M To End Sales Rep. Reimbursement Suit
• AstraZeneca And Damages In 'At-Risk' Generic Drug Launches
• TPP And The Next Frontier In International Arbitration
• Humana Urges Court Not To Allow Drug Cos.' Aggrenox Appeal
• Bayer Settles False Ad Suit Over WeightSmart Vitamins
• Fed. Circ. Remand Shows Nautilus May Have Little Impact
• Fed. Circ. Says Biosig Heart Monitor Patent Not Indefinite
• Impax Board Slams Investor Suit Over Compliance Gaffes
• Deals Rumor Mill: General Electric, Sobi, Caliber Midstream
• 5 Biotechs Set Stage For $415M Wave Of IPOs
• FDA Cracks Down On Medtronic Production Problems
• The Rising Stars Of Life Sciences Law
• Sandoz Fights Amgen's Bid To Halt 1st Biosimilar Launch
• Reed Smith Atty's Widow Slams GSK's Bid To Delay Trial
• Adaptimmune Set To Join Rush Of Cancer-Focused IPOs
• Baker & McKenzie Guides $109M Biocartis IPO
• FTC Warns Divestitures May Reach Beyond Problem Market
• Cooley Shows Off Life Sciences Dominance With Aduro IPO
• NJ High Court To Mull Preemption Battle In Reglan Claims
• INC Research's PE Backers Plan $237M Secondary Offering
• $16M Medical IP Judgment Relied On Witness Lies, Co. Says
• TWi, Takeda Settle Generic Dexilant Patent Suit
• Meunier Carlin Nabs Ex-King & Spalding IP Pro For Atlanta
• Supreme Court Rejects Teva's Reglan Preemption Dispute
• Celgene Grabs VC-Backed Cancer Biotech In $485M Deal
• CGL Policies In 4th Circ. May Cover Intentional Conduct
• IRS Slams Medtronic Bid To Seal Trial Docs In $561M Tax Row
• Mylan Nixes Teva's $40B Takeover Bid Amid Pharma Tussle
• The Latest In The Neverending Story Of Bard V. WL Gore
• HSBC, Deutsche, Barclays Led Antitrust Targets In 2014
• NY Southern District Becomes Antitrust Hotspot
• Dendreon Knocks Shareholders' Push For Equity Committee
• Former Pharma Exec Sues Inovio Over Stock Option Refusal
• Egyptian Diagnostic Co. Sets IPO Range For London Offering
• Biolitec's Contempt Fine Capped At $70M In IP Dispute
• Mylan's Sweetened $33B Perrigo Bid Gets Spurned
• Pharmacies Are Health Care Providers, Texas High Court Says
• Calif. County Defends Drug Cleanup Law To High Court
• Vinson Set To Lead Week's IPO Activity With 2 MLP Debuts
• PTAB Won't Review Chiesi Unit's 4 Hypertension Drug Patents
• Mylan Slapped With Patent Suit Over Generic Estrogen Patch
• EPA Agrees To Drop Superfund Suit For $1.7M Cleanup Costs
• Pa. Consumer Says Bayer's MiraLax Caused Kidney Damage
• National Storage, Apigee Mark Week's Only IPOs
• Bankruptcy Courts Remain Closed For Marijuana Businesses
• An Update On Hatch-Waxman Personal Jurisdiction Cases
• Protect Workers' Salary Info In Suit, Cymbalta Maker Says
• FDA Slams Supplement Cos. Over Untested Ingredient
• Sheppard Mullin Hires Ex-Greenberg Traurig M&A, Health Pro
• Vitacost Drops Beef With Ex-Counsel Over Botched IPO Docs
• Pfizer Near Settlement On Hormone Therapy Cancer Claims
• Celgene Drugs Join Hedge Fund's AIA Patent Hit List
• Weight Loss Biotech Gelesis Inches Closer To $52M IPO
• Why REMS Abuse Doesn't Belong In Antitrust Litigation
• Feds Hammer FedEx's Bid To Escape Pill Trafficking Charges
• MultiVir Sets IPO Terms Amid Run Of Cancer Biotech Debuts
• Allergan Pushes To Ax Eye Doctors' FCA Kickback Suit
• 5 Tips For Playing Both Sides Of The FCA Aisle
• Honigman Miller Snags Patent Pro For Ann Arbor Office
• Retailers Slam Pushback To Linking Effexor, Lipitor Appeals
• RB Recalls 1.5 Million Bottles Of Mislabeled Mucinex
• A Teva-Mylan Tie-Up Would Face Serious Antitrust Scrutiny
• Perrigo Wants Akorn's Antitrust Counterclaims Tossed
• GCs Name Most Elite Law Firms
• Hedge Fund's New Patent Attack Targets Biogen's MS Drug
• Prolias Blames PDI For Sinking Cornell Licensing Deal
• Millennium Must Pay Ameritox $8.6M In Patent Row, Jury Says
• Circumcision Clamp Makers Sued Over Amputated Penis
• Medtronic Win In 10th Circ. A Break For Device Cos.
• Enzo Investor Wants Co.'s Books In Wake Of Medicare Fraud
• Bio-Rad Investor Demands Books In Wake Of $55M FCPA Deal
• Rite Aid Wants To Join Lidoderm Patch Antitrust Battle
• Hedge Fund's Latest Patent Attack Targets Pharmacyclics
• Costco, 1-800 Contacts Stare Down Lens Makers In Utah
• Kirkland's Client Strategy Pays Off In Teva's Bid For Mylan
• Bristol-Myers Again Urges Justices To Assess Hepatitis Patent
• Warner Chilcott Beats Bayer's Infringement Claims In Yaz Suit
• Deals Rumor Mill: Baring Private Equity, Canon, BC Partners
• Medtronic Wins 10th Circ. Battle Against Infuse Injury Suit
• NY AG Says Doryx Dismissal Doesn't Doom Namenda Case
• House OKs Bill To Clarify Controlled Substance Oversight
• Fed. Circ. Won't Rehear Medtronic's IP Row With NuVasive
• FDA Fleshes Out Stance On Overseas Med Device Trials
• FDA Considers Heavier Regs For $2.9B Homeopathy Industry
• Troutman Sanders Adds Ex-Gordon & Rees Partner To IP Team
• Shasta Axes PharmaTech's $2M Glucose Strip Suit
• Brandon Capital Raises $154M For Aussie Biotech Ventures
• 3 Different Scenarios For Marijuana In Indian Country
• Schiff Hardin Snags IP, Pharma Pro From Winston & Strawn
• Teva-Mylan Deal Gains Traction As Perrigo Deal Is Rejected
• Cardinal Case Shines Light On FTC's Disgorgement Plans
• Roxane Says Jazz's Xyrem Patent Covers Law Of Nature
• J&J Says Costco Blind To Legality Of Contact Lens Pricing
• Pfizer Antibiotic Patent Escapes Apotex AIA Challenge
• FDA Bashes Otsuka Bid To Block Abilify Generics
• GNC Supplement Mislabeling Row Dropped By Plaintiff
• How To Prepare A Successful L-1 Visa Petition
• Cancer-Focused Blueprint Medicines Prepares $115M IPO
• GSK Dodges Avandia Side-Effect Disclosure Class Action
• Plaintiffs Say Shire Withholding Docs In Pay-For-Delay Suit
• Whistleblowers Appeal Dismissal Of Novartis FCA Xolair Suit
• Teva To Pay $512M To End Provigil Pay-For-Delay Dispute
• Daiichi Sankyo To Unload $3.6B Sun Pharma Stake
• 2015 Begins With A Drop In FCPA Enforcement Activity
• Drugmakers Slam FDA Study On Pill Shapes, Sizes
• FTC Inks 2nd Highest Disgorgement Deal With Cardinal Health
• A New Paradigm For Industrial Hemp Farming On Tribal Lands
• Tips For Guiding Your Client Through The Mediation Process
• The 100 Best Law Firms For Female Attorneys
• Law Firm Biases Continue To Thwart Women
• The Best Law Firms For Female Partners
• The Glass Ceiling Report
• High Court Urged To Reject Teva, Pliva Reglan Petitions
• J&J Can't Dodge $63M Verdict In Children's Motrin Case
• Otsuka Can't Pause Generic Abilify Launches, Judge Says
• AMS Settles More Than 350 Vaginal Mesh Suits
• Clifford Chance-Led REIT Set To Headline Week's 3 IPOs
• Cos. Say China Blocked Vitamin C Antitrust Suit Compliance
• State AGs Eying Pay-For-Delay Suits, Calif. Official Says
• FDA Should Ease Off-Label Regs Before Courts Do: PhRMA GC
• Jury Vindicates Pfizer In First Zoloft Birth Defect Trial
• 3rd Circ. Affirms Use Of Daubert To Fight Class Cert.
• Actavis Says 'Product-Hopping' Ruling Aids Namenda Appeal
• Drug Cos. Rip Bid To Merge Lipitor, Effexor Antitrust Appeals
• After FTC Fine, Cactus Juice Co. Loses Bid For Trademark
• Eli Lilly Beats Cymbalta Withdrawal Risk Suit
• Canadian High Court Squashes HIV Drug Securities Suit
• 7 Cos. Rake In $1.3B In Week's Flood Of IPO Activity
• Hony Capital Unloads $1.3B In Shares Of CSPC Pharma
• P&G Urges High Court To Stay Out Of Fixodent Evidence Claim
• MRI Radiation Therapy Maker ViewRay Pulls Plug On IPO
• Virginia's 'Rocket Docket' Continues To Roar
• DaVita To Settle FCA Suit After Witness Coaching Inquiry
• Pliva's Win In 5th Circ. Is A Blueprint To Beat 'Off-Label' Suits
• KemPharm IPO Raises $56M After Pricing Below Range
• Fla. House OKs 'Right To Try' Bill For Terminal Patients
• Law Firms Nix Hospital CEO's $60M Suit With 'Slam Dunk'
• Warner Chilcott Nabs Win In Generic Doryx Delay Row
• FTC To Dive Deep In Pay-To-Delay Analysis, Brill Says
• Deals Rumor Mill: Procter & Gamble, Hony Capital, Stemcor
• Natrol Buyer Tells Judge It Resolved Row With Ex-Owners
• WilmerHale Nabs Cooley Life Sciences M&A Pro In Palo Alto
• For Biosimilars Under Medicare, It Is Just The Beginning
• Ameritox Scores Jury Win In Urine Test Patent Row
• FTC Official Says Patent Settlement Side Deals Suspicious
• FTC Can Seek Disgorgement In Cephalon Suit, Judge Says
• FDA Pressed To Clarify Purity Standard On Injectables
• Medtronic Guts Over 140 Suits In Tenn. Federal Infuse Fight
• Abbott Wins Another Round In 20-Year Protein Patent Fight
• Cephalon Thins FCA Off-Label Marketing, Kickback Suit
• Otsuka Hits FDA With New Suit Over Abilify Generics
• Atty In NFLer's Stock Scheme Loses Insurance Defense Row
• Alibaba Sends Pharmacy Biz To Affiliate In $2.5B Deal
• Amgen Can't Halt Sandoz's Biosimilar Launch Ahead Of Appeal
• Rite Aid Hits Pharma Cos. With Generic Niaspan Antitrust Suit
• 2 Routes To Hourly Rates For Lawyers
• Clarus Nixes $86M IPO After Testosterone Drug Falls Flat
• A Prescription For Sound DEA Compliance
• Sidley Austin Adds Ex-O'Melveny M&A Pro in New York
• Branch Law Firm Says Former Atty Bound To Arbitrate Claims
• 3 Biotechs Rake In $272M In IPO Rush
• SIGA Asks Judge To Nix Financial Adviser's Legal Fee Claims
• Judge Allows Most Claims In Suboxone MDL To Move Forward
• Jones Day Urges 8th Circ. To Nix Training-Video Sanction
• FDA Panel Backs Safety Of AstraZeneca Diabetes Drug
• Bausch & Lomb, Alcon Challenge Utah Contact Lens Law
• FTC's Wright Slams Shortcuts In Evaluating IP Antitrust Claims
• Michael J. Fox Foundation Settles Over Spoiled Lab Samples
• Texas Firms Botched Case Against Bayer's Mirena, Suit Says
• HHS Inspector To Scrutinize Increased Generic Drug Costs
• ITC Can't Claim Digital Download Authority, Fed. Circ. Told
• PhRMA Presses Case For Dumping 340B Orphan Drug Rule
• Sullivan Guides $930M Private Sale Of China TCM Shares
• Enzo Says Fed. Circ. Ruling In Patent Row Flouts Teva
• Smith & Nephew Sued Over Failed Knee Replacement
• BakerHostetler Adds International Arbitration Partner In DC
• Rising Star: Sidley Austin's Jaime Jones
• Concordia Nabs $735M In Upsized Offering To Back Covis Buy
• Immuno-Oncology Biotech Aduro Boosts IPO Target To $119M
• Ex-Execs Of Co. Sold To J&J Charged With Securities Fraud
• Questcor Pays $38M To Settle Securities Class Action
• J&J Stays Clear Of Time-Barred FCA Claims, 3rd Circ. Rules
• 7th Circ. Revives Suit Over Abbott Off-Label Scheme
• DLA Piper Snags Another Morgan Lewis Atty For Philly Office
• Shire, Actavis Spar At Fed. Circ. Over Teva's Impact
• 2nd Circ. Wary Of Anti-Competitive Intent In Namenda Plan
• Galderma, Actavis Settle Generic Epiduo Suit Ahead Of Trial
• Teva Urges High Court To Review Disputed Labeling Theory
• Rising Star: Paul Hastings' Eric Dittmann
• 510(k) In Patent Litigation: Applicants Should Be Cautious
• How To Weather Media Inquiries In High-Profile Cases
• FDA Reverses Broad Abilify Approval, Otsuka Says
• Viking Therapeutics Sets Terms For Downsized $22.5M IPO
• W.Va. High Court Affirms 20 Zoloft Dismissals
• Geron Gets Shareholder Action Over Cancer Drug Trimmed
• Ropes & Gray, Jones Day Guide Week's 2 IPOs Raising $105M
• Etsy, Party City Lead $1.2B Pack Of IPOs Set To Break Lull
• Rising Star: Hogan Lovell's Adam Bellack
• Kramer Levin Snags 2 Life Sciences IP Pros In NY
• SEC Drops Probe Of Bankrupt Pharma Co. Dendreon
• Prograf Antitrust MDL Lawyers Seek $34M In Fees
• Will The Pendulum Swing Back In IPR Proceedings?
• Convicted Atty In Penny Stock Scam Can't Revisit SEC Ruling
• 5th Circ. Frees Pliva, Others From Generic Reglan Claims
• Judge Won't Sanction Skin Treatment Co. For 'Stinker' Ch. 11
• Merck Fights Bid To Strike Replies In K-Dur Pay-For-Delay Suit
• Fed. Circ. Affirms Sandoz Loss In Generic AzaSite Case
• Bayer Says Tossing Brain Supplement Suit Is A No-Brainer
• Edge Therapeutics Raises $72M For Brain Injury Drug
• P&G, Wal-Mart Escape Fixodent MDL After Experts Excluded
• Siga Creditors Seek Probe Of Execs' 'Bad Faith' Conduct
• Panel Sends Medical Marijuana Bill To Full Fla. Senate
• Booming Pharma Biz Means Big Money For Some Law Firms
• Valeant, Pershing End Spat With Allergan Over Takeover Bid
• Medtronic Urges Fed. Circ. To Toss NuVasive Surgery Patent
• Judge Grants Workers Expanded Data in Forest Sex Bias Suit
• 4 Tips For Keeping Civil FCA Suits From Going Criminal
• Rising Star: BakerHostetler's Lee Rosebush
• Some Declaratory Judgment Guidance For ANDA Litigants
• 2 Cases Audit Firm Defendants Can Rely On
• Zoloft Plaintiffs Face High Stakes In First Birth Defect Trials
• Abbott Wants GSK HIV Suit Axed Weeks Before Retrial
• P&G, Wal-Mart To End Fixodent MDL After Crushing Ruling
• FDA Fleshes Out Stance On Fast-Track Device Approvals
• Feds Must Add Details In Sanofi Insider Trading Case: Judge
• Purdue's Anti-Abuse OxyContin Patent Claims Found Invalid
• Biolitec Exec Still Ducking Depositions, Sanctions Bid Says
• Judge Chides FDA For Stalling Otsuka's Abilify Suit
• 3rd Circ. Says Comcast Forces Class Cert. Redo In Ex-J&J Suit
• Full Fed. Circ. Won't Review Standard In $1B Gore-Bard Suit
• Dendreon Slams Shareholders' Bid To Stay $495M Sale
• Fed. Circ. Affirms Another AbbVie Win In Humira Patent Case
• American Capital Pockets $750M In Mirion Technologies Sale
• Biotronik Fights Discovery Motion In $1.1M FCA Fees Row
• Mylan Makes $29B Bid To Buy Pharma Co. Perrigo
• 'Cosmeceutical' Classification In Regulatory Crosshairs
• Lessons From The 1st Biopharma Inter Partes Reviews
• AbbVie Says FTC Can't Fight By Own Rules In Pay-For-Delay
• Boehringer Asks DC Circ. To Rethink Doc Ruling In FTC Probe
• Texas, Feds Recover $25M From Glenmark For Inflated Prices
• Lead Plaintiff Drops DaVita Dialysis Claims
• JPML Centralizes 15 Suits Over Benicar Side Effects In NJ
• FDA Warns Hospira Again For Poor Practices In Italy
• 3rd Circ. Says Drug Cos. Can't Send Effexor Suit To Fed. Circ.
• NY Pharmacy Sues CVS Over Suspension, Withheld Money
• Intercept Raises $367M As More Biotechs Pursue Follow-Ons
• Fed. Circ. Affirms Most Of $76M AstraZeneca Prilosec IP Win
• UK Cancer-Focused Biotech Adaptimmune Eyes $150M US IPO
• Hedge Fund Adds Jazz Drug To List Of AIA Review Targets
• Calif. Biotech Eyes $86M IPO To Fund Muscular Dystrophy Med
• Accutane Ruling Could Have Ripple Effect Beyond NJ
• Ex-FDA Chief Named Institute Of Medicine's Foreign Secretary
• Rite Aid Files Latest Antitrust Suit Over Solodyn Generic Deals
• Spinal Therapy Co. Ducks Investor Class Action
• Twin City Needn't Cover Medical Co.'s FCA Suit, Judge Says
• Texas Court Says Latex Glove Maker Must Indemnify Dealer
• Vitamin Shoppe Says Studies Back Up Protein Labels
• Cannabis And Indian Country: Basics 101
• The 5 Biggest M&A Moves Of The 1st Quarter
• Drug Cos. Want 2nd Circ. To Hear Bid To Nix Aggrenox Claims
• Abbott Says FCA Suit Over Preapproval Promotion Fails
• FTC Aims To Limit Cephalon Evidence In Pay-For-Delay Trial
• Bristol-Myers Set To Partner With Gene Therapy Co. UniQure
• Novartis To Pay $12.3M, Royalties To End IP Row With Juno
• Wyeth, Teva Push To Move Effexor Appeal To Fed. Circ.
• Natrol Ch. 11 Buyer Sues Ex-Owners Over 'Sham' Contract
• High Court Won't Hear After-Acquired Evidence Use Appeal
• Novartis Defends Exelon Patents At Fed. Circ.
• 3 VC-Backed Drugmakers Fire Up $200M In IPO Plans
• AbbVie Tries To Get Shire Shareholders' Suit Tossed
• FDA Outlines Steps For Changing Drug Safety Controls
• Pain-Pump Seller, Ironshore Settle $10M Coverage Row
• Aduro Prepares $80M IPO After Inking Novartis Partnership
• 3rd Circ. Urged To Merge Lipitor, Effexor Antitrust Appeals
• Rite Aid Latest To File Aggrenox Pay-For-Delay Suit
• Fresenius Says Whistleblower Disclosures Are Already Public
• Merck Wants FCA Claim Tossed After Millennium Escapes Suit
• FDA Looks To Duck Firm's Suit Over J&J Risperdal Docs
• 3 Tips For Firms With Lawyers On Both Sides Of A Deal
• Class Says FDA Ruling Backs Nexium Pay-For-Delay Retrial
• Travelers Says No Duty To Defend Medical Co. In IP Suit
• Taxation With Representation: Wachtell, Simpson, Cooley
• Painkiller Developer Collegium Pharmaceutical Eyes $86M IPO
• Latham To Lead Week's Only IPO Expected To Top $50M
• FedEx Civil Suit Halted Pending Criminal Drug Investigation
• Teva Strikes $24M Deal To Exit Nexium Pay-For-Delay Suit
• Obesity Capsule Maker Wants $60M IPO After $22M Financing
• Fed. Circ. Urged To Rehear Medtronic's IP Row With NuVasive
• Medtronic Pays $4.4M To End Device Sale Investigation
• Aggrenox Doesn't Apply In Provigil Pay-For-Delay Suit: Teva
• NC Shutters Compounding Pharmacy, Recalls Drugs
• Takeda Calls $2.2B Actos Settlement Report 'Rumor'
• Diet Pill Maker, Snooki Can't Dodge False Ad Class Action
• Bryan Cave Can't Get Ex-Client's Docs In $1.5M Fee Row
• Shire Drugs Are Next Targets Of Hedge Fund's AIA Reviews
• Roche's New Accutane Warning Label OK, Judge Rules
• PharMerica Can't Nix FCA Suit Under First-To-File Bar
• Natrol Gets Green Light On Ch 11. Plan Disclosures
• State AGs Urge Lawmakers To Investigate Supplement Cos.
• CryoLife Appeals Rare Injunction In Patent Case
• Generic Cases Still Face Tough Odds After High Court Snub
• Pelvic Mesh Mass Tort Cases Can Stay In Philly, Judge Says
• NJ Doctors Get Prison Time In Lab Services Bribe Scheme
• Baxter, J&J Strike Deal To End Floseal Patent Fight
• Johns Hopkins Faces $1B Suit Over 'Horrific' Syphilis Study
• Novartis Docs Privileged In Kickback Case, Judge Says
• Penn Wins Atty Fees Under Octane In Alzheimer's Patent Suit
• FDA Finalizes Guidance On Abuse-Deterrent Narcotics
• Final Hagens Berman Thalidomide Claim Too Late, Judge Says
• FDA Must Block Off-Label Diabetes Drug Promos, Group Says
• Sarepta Therapeutics Securities Class Action Gets The Boot
• USC Settles Ex-Football Player's Pain Med Suit At 11th Hour
• Here's How The CARERS Act Could Change Cannabis Policy
• DLA Piper Lures Life Sciences Deal Maker From Morgan Lewis
• Novartis Faces Zometa Suit Despite Delay After Plaintiff Death
• Goodwin-Led Insulin Pump Maker Asante Pulls Plug On IPO
• Pfizer Dodges Centrum Multivitamin False Ad Class Action
• Nutrex, GNC, Others Sued Over Falsely Marketed Supplements
• Cochlear Gets New Trial After $131M IP Verdict
• So Your H-1B Petition Is Not Selected — What Now?
• Ethics In The Tech Age: What Every Lawyer Should Consider